VERACYTE, INC.
Company Stats
- Market Cap
- $3.7B
- as of Sep 30, 2026
- Shares Outstanding
- 80.4M
- Free Float
- 98.4%
Income Statement
- Revenue
- $517.1M
- Operating Income
- $57.8M
- Net Income
- $66.4M
- EBITDA
- $79.2M
- Non-cash Impairment
- $20.5M
- Revenue Growth, 3Y
- 20.4%
- FCF Margin, 3Y Avg
- 16.1%
- FCF Margin, Worst Year
- 9.5%
Cash Flow
- Free Cash Flow
- $126.6M
- FCF Yield
- 3.4%
- Owner FCF Yield
- 2.2%
Balance Sheet
- Cash & Equivalents
- $362.6M
Returns & Capital
- SBC, 3Y Avg
- $37.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $517.1M | $126.6M | 24.5% |
| FY2024 | $445.8M | $63.8M | 14.3% |
| FY2023 | $361.1M | $34.3M | 9.5% |
| FY2022 | $296.5M | -$1.0M | -0.3% |
| FY2021 | $219.5M | -$37.0M | -16.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Veracyte to Buy Convergent Genomics for $150 Million